Cargando…
P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430138/ http://dx.doi.org/10.1097/01.HS9.0000846604.67185.0c |
| _version_ | 1784779670348103680 |
|---|---|
| author | Rodriguez, C. Kaufman, J. L. Laubach, J. Sborov, D. W. Reeves, B. Chari, A. Silbermann, R. Costa, L. J. Anderson, L. D. Nathwani, N. Shah, N. Bumma, N. Jakubowiak, A. Orlowski, R. Z. Pei, H. Cortoos, A. Patel, S. Lin, T. S. Richardson, P. G. Voorhees, P. M. |
| author_facet | Rodriguez, C. Kaufman, J. L. Laubach, J. Sborov, D. W. Reeves, B. Chari, A. Silbermann, R. Costa, L. J. Anderson, L. D. Nathwani, N. Shah, N. Bumma, N. Jakubowiak, A. Orlowski, R. Z. Pei, H. Cortoos, A. Patel, S. Lin, T. S. Richardson, P. G. Voorhees, P. M. |
| author_sort | Rodriguez, C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430138 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94301382022-08-31 P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN Rodriguez, C. Kaufman, J. L. Laubach, J. Sborov, D. W. Reeves, B. Chari, A. Silbermann, R. Costa, L. J. Anderson, L. D. Nathwani, N. Shah, N. Bumma, N. Jakubowiak, A. Orlowski, R. Z. Pei, H. Cortoos, A. Patel, S. Lin, T. S. Richardson, P. G. Voorhees, P. M. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430138/ http://dx.doi.org/10.1097/01.HS9.0000846604.67185.0c Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Rodriguez, C. Kaufman, J. L. Laubach, J. Sborov, D. W. Reeves, B. Chari, A. Silbermann, R. Costa, L. J. Anderson, L. D. Nathwani, N. Shah, N. Bumma, N. Jakubowiak, A. Orlowski, R. Z. Pei, H. Cortoos, A. Patel, S. Lin, T. S. Richardson, P. G. Voorhees, P. M. P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN |
| title | P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN |
| title_full | P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN |
| title_fullStr | P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN |
| title_full_unstemmed | P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN |
| title_short | P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN |
| title_sort | p934: daratumumab + lenalidomide, bortezomib, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a post hoc analysis of sustained minimal residual disease negativity from griffin |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430138/ http://dx.doi.org/10.1097/01.HS9.0000846604.67185.0c |
| work_keys_str_mv | AT rodriguezc p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT kaufmanjl p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT laubachj p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT sborovdw p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT reevesb p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT charia p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT silbermannr p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT costalj p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT andersonld p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT nathwanin p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT shahn p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT bumman p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT jakubowiaka p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT orlowskirz p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT peih p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT cortoosa p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT patels p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT lints p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT richardsonpg p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin AT voorheespm p934daratumumablenalidomidebortezomibanddexamethasoneintransplanteligiblenewlydiagnosedmultiplemyelomaaposthocanalysisofsustainedminimalresidualdiseasenegativityfromgriffin |